(Q24243837)

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

A pilot trial of olanzapine for the treatment of cocaine dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

Pergolide mesylate for cocaine abuse: a controlled preliminary trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

A placebo-controlled screening trial of olanzapine, valproate, and coenzyme Q10/L-carnitine for the treatment of cocaine dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

A double-blind placebo-controlled pilot study of risperidone for decreasing cue-elicited craving in recently withdrawn cocaine dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

Risperidone diminishes cocaine-induced craving

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

Effect of flupenthixol on subjective and cardiovascular responses to intravenous cocaine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

Significant interaction between clozapine and cocaine in cocaine addicts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

Outpatient treatment of 'crack' cocaine smoking with flupenthixol decanoate. A preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

Risperidone for the treatment of cocaine dependence: randomized, double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

Effects of intravenous cocaine are partially attenuated by haloperidol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

The Cochrane collaboration: preparing, maintaining, and disseminating systematic reviews of the effects of health care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

Abstinent opiate abusers exhibit conditioned craving, conditioned withdrawal and reductions in both through extinction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

Characteristics and pretreatment behaviors of clients entering drug abuse treatment: 1969 to 1993.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

Methadone maintenance at different dosages for opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

Replacement medication for cocaine dependence: methylphenidate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

The assessment of anxiety states by rating

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

Development of a Rating Scale for Primary Depressive Illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

Incentives improve outcome in outpatient behavioral treatment of cocaine dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

Reliability and validity of the Cocaine Selective Severity Assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

Neurochemical changes in cocaine withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

Antidepressants for cocaine dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

The Fifth Edition of the Addiction Severity Index

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

Benzodiazepines for alcohol withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

Anticonvulsants for alcohol withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

Recreational drug consumers: who seeks treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

Dopamine agonists for cocaine dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

Change in health-related problems of cocaine consumption in Catalonia, Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

The development of a cocaine craving questionnaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

Changes in patterns of drug injection concurrent with a sustained reduction in the availability of heroin in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

The addicted human brain: insights from imaging studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

PET measures of amphetamine-induced dopamine release in ventral versus dorsal striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

Clinical applications of visual analogue scales: a critical review.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006306.PUB2